{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-003432","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.979008+00:00","generated_at":"2026-05-24T03:53:47.507991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone","bullets":["Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).","Cash and short-term investments $44.9M at Dec 31, 2024, down from $96.3M at Dec 31, 2023; runway into H1 2026 based on plans.","Topline Phase 2 data for NDV-01 (bladder cancer) expected at AUA April 26-29, 2025; Phase 2b-ready sepranolone for Tourette syndrome.","Re-evaluating further development of REL-P11 due to competitive landscape in metabolic disease.","R&D expense FY2024 $46.2M, down from $54.8M; G&A $37.7M vs $48.9M, reflecting cost-saving measures."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-003432","json":"https://secwatch.observer/filing/0001013762-25-003432.json","markdown":"https://secwatch.observer/filing/0001013762-25-003432.md","text":"https://secwatch.observer/filing/0001013762-25-003432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/0001013762-25-003432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/ea0236006-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:53:47.507991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}